Skip to content
Clinical Trials – home
Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 70

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Study of Venetoclax, Ibrutinib, and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Venetoclax
  • Sponsor:Ospedale San Raffaele S.r.l.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Preventing Liver Recurrence in Patients with Intrahepatic Cholangiocarcinoma Using Floxuridine via Hepatic Arterial Infusion Pump

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Metformin for Patients with Esophageal Cancer to Enhance Chemoradiotherapy Response

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Hydrochloride
  • Sponsor:Amsterdam UMC Stichting

Study on NECVAX-NEO1 and Paclitaxel Albumin-Bound for Patients with Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Necvax-Neo1
  • Sponsor:NEC Bio Therapeutics GmbH

Ewing's sarcoma

Recruiting

Study on the Effectiveness and Safety of Naxitamab for Patients with Refractory Ewing's Sarcoma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab
  • Sponsor:Instytut Matki I Dziecka

Study of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Study on Mocravimod for Adults with Acute Myeloid Leukemia Undergoing Stem Cell Transplant

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mocravimod
  • Sponsor:Priothera S.A.S.

Breast cancer

Recruiting

Study of Fertility Preservation Using Tamoxifen, Follitropin Beta, Cetrorelix and Choriogonadotropin Alfa in Women with Breast Cancer Before Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cetrorelix
  • Sponsor:Institut De Cancerologie De L Ouest

Study of Atezolizumab with Drug Combination for Patients with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione GONO G.I.

Study on Sequential Treatment with Gemcitabine, Paclitaxel, and FOLFIRINOX for Patients with Locally Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Institut Regional Du Cancer De Montpellier

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tub-040
  • Sponsor:Gilead Sciences Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.